Comment From Breakthrough Breast Cancer Re Lapatanib (Tyveb) Offers Hope After Hercep
Comment from Breakthrough Breast Cancer following the announcement that lapatinib (Tyverb) has been given a licence in the European Union as a treatment for women with HER2-positive advanced breast cancer, whose disease has stopped responding to Herceptin.Dr Alexis Willett, Policy Manager at Breakthrough Breast Cancer says: "Patients with advanced breast cancer usually have limited treatment options.
More... |
All times are GMT -7. The time now is 04:34 AM. |
Powered by vBulletin® Version 3.8.7
Copyright ©2000 - 2024, vBulletin Solutions, Inc.
Copyright HER2 Support Group 2007 - 2021